- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Q&A: Nathan Tinker, New York Biotechnology Association
While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association.
Nathan Tinker
While at the 2014 New York BIO Conference (NYBIO), Applied Clinical Trials‘ Moe Alsumidaie spoke to Nathan Tinker, Executive Director at the New York Biotechnology Association, about challenges in early phase development.
The New York Biotechnology Association is dedicated to the development and growth of New York State-based bioscience related industries and institutions.
Moe Alsumidaie: How is NYBIO Changing?Nathan Tinker: When the organization was founded over 25 years ago, it was a biotechnology peer planning organization. However, it was clear that biopharmaceutical companies rapidly became a part of the equation. In the last two years, we have seen growth in the agricultural sciences industry, medical devices, combination therapies. Additionally, hospitals, clinicians, and payers/providers became more engaged in early-stage R&D development. Our objective is to take advantage of this culture and fully encompass what BIO has become on both national and policy fronts.
For the rest of the interview, click here.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Fake Weight Loss Drugs: Growing Threat to Consumer Health
October 25th 2024In this episode of the Pharmaceutical Executive podcast, UpScriptHealth's Peter Ax, Founder and CEO, and George Jones, Chief Operations Officer, discuss the issue of counterfeit weight loss drugs, the potential health risks associated with them, increasing access to legitimate weight loss medications and more.
